Senores Pharmaceuticals Limited
All news and filings related to Senores Pharmaceuticals Limited.
View all news & filings- Medium impact
Senores Pharma's 9th AGM: Voting Results Announced for Key Resolutions
Senores Pharmaceuticals Limited's 9th AGM, held on September 25, 2026, saw all resolutions passed. Key approvals include the FY26 financial statements, re-appointment of two directors, appointment of an independent director, and the 'Senores Pharmaceuticals Employee Stock Option Scheme 2026' along with ESOP grants to subsidiary employees.
Read the summary - Low impact
Senores Pharmaceuticals Holds 9th AGM on Sep 25, 2026, Discusses Financials & ESOPs
Senores Pharmaceuticals Limited held its 9th AGM on September 25, 2026. Key discussions included adopting FY26 financial statements, re-appointing directors, appointing an independent director, and approving the ESOP scheme 2026.
Read the summary - Low impact
Senores Pharmaceuticals Closes Trading Window From Oct 1 For Q2 FY27 Results
Senores Pharmaceuticals Limited will close its trading window from October 1, 2026. This is to comply with SEBI PIT regulations pending the announcement of un-audited financial results for the quarter and half-year ending September 30, 2026.
Read the summary - Low impact
Senores Pharma Clarifies Volume Movement, No Price-Sensitive Info Pending
Senores Pharmaceuticals Limited has clarified a recent surge in trading volume, stating there is no undisclosed price-sensitive information or pending corporate actions. The company confirmed its compliance with SEBI (LODR) Regulations and its commitment to timely disclosures.
Read the summary - Medium impact
Senores Pharma Subsidiary Completes USFDA Inspection with No GMP Observations
Senores Pharmaceuticals Limited's subsidiary, Apna Pharma Private Limited, successfully completed a USFDA inspection at its Vadodara facility from Sep 07-11, 2026. The inspection resulted in only one minor procedural observation, with no GMP-related findings. The subsidiary will submit its response accordingly.
Read the summary - Low impact
Senores Pharma Announces 9th AGM on Sep 25, 2026, with E-voting Facility
Senores Pharmaceuticals Limited will hold its 9th AGM on September 25, 2026, via video conference. Shareholders can e-vote from September 22-24, 2026, through the Linkintime portal. The AGM notice and related documents are available on the company website and stock exchanges.
Read the summary - Low impact
Senores Pharma Announces 9th AGM on Sep 25, 2026, Releases Annual Report
Senores Pharmaceuticals will hold its 9th AGM on September 25, 2026, via VC/OAVM. The company released its Annual Report for FY 2025-26. E-voting is open from September 22 to September 24, 2026. The cut-off date for eligibility is September 18, 2026.
Read the summary - Low impact
Senores Pharma to Attend Investor Conference by Elara Capital on Sep 2, 2026
Senores Pharmaceuticals Limited officials will attend an Investor Conference hosted by Elara Capital Group and 1x1 Meetings on September 2, 2026. The meeting, held physically in Mumbai, will focus on publicly available information.
Read the summary - Low impact
Senores Pharma Announces 9th AGM on Sep 25, 2026
Senores Pharmaceuticals Limited will hold its 9th Annual General Meeting (AGM) on September 25, 2026. The meeting will be conducted via Video Conferencing/Other Audio-Visual Means. The announcement was published on August 27, 2026.
Read the summary - Medium impact
Senores Pharma Appoints New CS, Independent Director; Approves ESOP & Overseas Subsidiaries
Senores Pharmaceuticals appointed Mrs. Shilpa Sharma as Company Secretary and Mr. Viranchi Arvindbhai Shah as Independent Director. The company approved the ESOS 2026 scheme for 4,72,000 options. Additionally, it will incorporate subsidiaries in Mexico and Canada to expand international presence.
Read the summary - Medium impact
Senores Pharma Issues ₹62 Crore Corporate Guarantee for Subsidiary's Credit Facility
Senores Pharmaceuticals Limited has issued a corporate guarantee of ₹62 Crores for its subsidiary, Apnar Pharma Private Limited. The guarantee is for credit facilities availed by the subsidiary from ICICI Bank Limited and is valid until the closure of these facilities. The company states it has no impact beyond a contingent liability.
Read the summary - Low impact
Senores Pharma to attend Investor Conference hosted by Antique Stock Broking on Aug 25
Senores Pharmaceuticals Limited will attend an Investor Conference hosted by Antique Stock Broking on August 25, 2026. The meetings will be held physically in Mumbai, starting at 11:00 AM IST. Discussions will be limited to publicly available information, with no UPSI to be shared.
Read the summary - Medium impact
Senores Pharma Shareholders Approve Key Resolutions via Postal Ballot
Senores Pharmaceuticals Limited shareholders approved all Ordinary and Special Resolutions via postal ballot. Key approvals include material related party transactions and enhancements to loan/guarantee limits. Shareholders also approved variations and extensions for IPO proceeds utilization.
Read the summary - High impact
Senores Pharmaceuticals Q1 FY27 Earnings Call Transcript Released
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180 crore, up 36% YoY. PAT grew 56% to ₹31 crore, with EBITDA up 87% to ₹54 crore. The company forecasts FY27 revenue growth of 30-40% and PAT growth of 50-60%. Regulated markets grew 42% and emerging markets 30%.
Read the summary - Low impact
Senores Pharma Publishes Q1 FY27 Unaudited Financial Results
Senores Pharmaceuticals Limited published its unaudited consolidated and standalone financial results for the quarter and financial year ended June 30, 2026. The results were published on July 28, 2026, in the Financial Express. The company also updated its website with the information.
Read the summary - Low impact
Senores Pharma Q1 FY27 Earnings Call Recording Available Online
Senores Pharmaceuticals Limited has made the audio recording of its Q1 FY27 earnings conference call available online. The call, held on July 27, 2026, discussed unaudited financial results for the quarter ended June 30, 2026. No UPSI was shared during the call.
Read the summary - Low impact
Senores Pharma: No Deviation in Fund Utilization for Q1FY27
Senores Pharmaceuticals confirms no deviation in fund utilization for Q1FY27. Funds of ₹95 crore were raised via preferential issue of warrants. For the quarter ended June 30, 2026, ₹16.91 crore was utilized for working capital, subsidiaries, and general corporate purposes.
Read the summary - Low impact
Senores Pharma: No Deviation in IPO Fund Utilization for Q1 FY27
Senores Pharmaceuticals confirms no deviation in IPO fund utilization for the quarter ended June 30, 2026. The company raised ₹500 Crores via IPO in December 2024. While most allocations are utilized as planned, minor delays exist in capital expenditure funding for a manufacturing facility, with shareholder approval sought for adjustments.
Read the summary - Low impact
Senores Pharma: Monitoring Agency Report for Q1FY27 Shows IPO Fund Utilization
Senores Pharmaceuticals Limited filed its Monitoring Agency Report for Q1FY27, detailing IPO fund utilization. The report highlights delays in setting up a sterile injection manufacturing facility, with revised timelines and object variations sought. Unutilized IPO proceeds stood at ₹100.54 crore as of June 30, 2026. The Audit Committee and Board have reviewed the report.
Read the summary - Medium impact
Senores Pharma Releases Q1FY27 Investor Presentation Highlighting 36% Revenue Growth
Senores Pharmaceuticals Limited reported Q1 FY27 results with revenue up 36% YoY to ₹180.2 crore and EBITDA up 87% to ₹53.8 crore. PAT increased 56% to ₹30.7 crore. The company highlighted growth in regulated and emerging markets and its expanding product pipeline.
Read the summary - High impact
Senores Pharma Q1 FY27 Revenue Surges 36% to ₹180 Crore, PAT Up 56% to ₹31 Crore
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180.2 crore, a 36% year-on-year increase. PAT grew 56% to ₹31 crore. Regulated Markets revenue surged 42% and Emerging Markets revenue rose 30%. The company expanded its ANDA portfolio to 58 and expects sustained growth in FY27.
Read the summary - Medium impact
Senores Pharma Q1 FY27 Revenue Up 36% to ₹180 Cr; Appoints Anjali Shah as SMP
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180 crore, a 36% YoY increase. PAT grew 56% to ₹31.20 crore, with EBITDA up 87% to ₹54 crore. The company appointed Ms. Anjali Shah as Senior Management Personnel (SMP) effective July 27, 2026.
Read the summary - High impact
Senores Pharma Q1 FY27: Revenue Up 36% to ₹180 Cr, PAT Rises 56% to ₹31 Cr
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180.21 crore, up 35.9% YoY. PAT increased 56% to ₹30.45 crore. EBITDA grew 87% to ₹54 crore. Regulated markets revenue rose 41.9% to ₹127.8 crore. Ms. Anjali Shah appointed as Senior Management Personnel.
Read the summary - High impact
Senores Pharmaceuticals Q1 FY27: Revenue up 36% to ₹180 Cr, PAT up 56% to ₹31 Cr
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180.21 crore, up 36% YoY. PAT grew 56% to ₹30.45 crore. Regulated Markets revenue surged 42%, and Emerging Markets grew 30%. EBITDA increased 87% with margin expansion. Ms. Anjali Shah was appointed Senior Management Personnel.
Read the summary - Low impact
Senores Pharmaceuticals to Host Q1FY27 Earnings Conference Call on July 27
Senores Pharmaceuticals will hold its Q1FY27 earnings conference call on Monday, July 27, 2026, at 05:15 PM IST. The call will follow the announcement of the company's unaudited consolidated and standalone financial results for the quarter ended June 30, 2026.
Read the summary - Low impact
Senores Pharma Dispatches Postal Ballot Notice, Invites E-voting
Senores Pharmaceuticals Limited has dispatched its Postal Ballot Notice and e-voting intimations. The details were published in Financial Express on July 3, 2026, and are available on the company's website. This action is in compliance with SEBI regulations.
Read the summary - Medium impact
Senores Pharma Seeks Shareholder Approval for Related Party Transactions and IPO Fund Utilization
Senores Pharmaceuticals is seeking shareholder approval via postal ballot for material related party transactions totaling over ₹750 Crores with Havix Group, Ratnatris Pharma, and Apnar Pharma for FY 2026-27. It also seeks approval for enhanced loan/guarantee limits up to ₹750 Crores and revised IPO fund utilization plans. E-voting is from July 5 to August 3, 2026.
Read the summary - Medium impact
Senores Pharma to seek shareholder nod for IPO proceeds variation of ₹100 Crore
Senores Pharmaceuticals approved a variation in IPO proceeds utilization. ₹100.016 crore will be reallocated from the total IPO proceeds of ₹500 crore. Shareholder approval via postal ballot is required. The decision was recommended by the Audit Committee.
Read the summary - Low impact
Senores Pharma: Vinay Mishra Relieved as Company Secretary June 10
Senores Pharmaceuticals Limited confirms Mr. Vinay Kumar Mishra's departure as Company Secretary and Compliance Officer, effective June 10, 2026. Mr. Swapnil Jatinbhai Shah and Mr. Deval Rajnikant Shah are now authorized for disclosures. This follows his resignation intimation on May 14, 2026.
Read the summary - Low impact
Senores Pharma: Mr. Vinay Kumar Mishra ceases as Company Secretary & Compliance Officer on June 10, 2026
Senores Pharmaceuticals Limited announced that Mr. Vinay Kumar Mishra will cease as Company Secretary and Compliance Officer effective June 10, 2026. Mr. Swapnil Jatinbhai Shah and Mr. Deval Rajnikant Shah are authorized for disclosures.
Read the summary - Low impact
Senores Pharma to Attend Investor Conference by Macquarie Group on June 9
Senores Pharmaceuticals Limited will attend an investor conference hosted by Macquarie Group on June 09, 2026. The meeting, scheduled from 1:30 PM to 2:30 PM IST in Mumbai, will focus on publicly available information.
Read the summary - Low impact
Senores Pharma to Attend Investor Conference on May 28, 2026
Senores Pharmaceuticals Limited officials will attend an investor conference on May 28, 2026, hosted by 360 One Capital Group / 1x1 Meetings in Mumbai. Discussions will be limited to publicly available information, with no unpublished price sensitive information to be shared.
Read the summary - Low impact
Senores Pharma to attend Investor Conference hosted by Ambit Capital on May 25
Senores Pharmaceuticals Limited will attend an investor conference hosted by Ambit Capital Group / 1x1 Meetings. The physical meeting is scheduled for May 25, 2026, at 11:00 AM IST in Mumbai. Discussions will be limited to publicly available information.
Read the summary - High impact
Senores Pharmaceuticals FY26 Revenue at ₹663 Crore, Up 62%; PAT Grows 108% to ₹122 Crore
Senores Pharmaceuticals reported FY26 revenue of ₹663 crore, a 62% increase, and PAT of ₹122 crore, up 108%. The company projects FY27 revenue growth of 30-40% and PAT growth of 50-60%. In Q4FY26, they acquired 75% stake in Apnar Pharma and also acquired Zoraya Pharmaceuticals in Q3FY26. A strategic joint venture called Amerisyn was formed in April.
Read the summary - Low impact
Senores Pharma Publishes Audited Financial Results for FY26
Senores Pharmaceuticals Limited published its audited financial results for the quarter and year ended March 31, 2026. The results, covering both consolidated and standalone financials, were published in the Financial Express on May 15, 2026. The company has uploaded the information to its website.
Read the summary - Low impact
Senores Pharma Releases Audio Recording of Q4 FY26 Earnings Conference Call
Senores Pharmaceuticals Limited has released the audio recording of its earnings conference call held on May 14, 2026. The call focused on the audited financial results for the quarter and fiscal year ended March 31, 2026. The recording is available on the company's investor relations website.
Read the summary - Low impact
SENORES: No Deviation in Fund Utilization for Q4FY26 Preferential Issue
Senores Pharmaceuticals confirms no deviation in fund utilization for its ₹95 crore preferential issue of warrants for the quarter ended March 31, 2026. Funds were raised on March 28, 2026. The statement was approved by the Audit Committee and Board on May 14, 2026.
Read the summary - High impact
Senores Pharma Q4&FY26 Investor Presentation Released
Senores Pharma released its Q4 & FY26 investor presentation. FY26 Total Income reached ₹664 crore (up 62%), EBITDA ₹199.6 crore (up 96%), and PAT ₹121.5 crore (up 108%). Key strategies include acquisitions and U.S. market entry. Cash flow from operations improved to ₹75 crore.
Read the summary - Low impact
Senores Pharma: No Deviation in IPO Fund Use for Q4FY26
Senores Pharmaceuticals Limited reports no deviation in IPO fund utilization for Q4FY26. The company utilized ₹394.98 crore out of ₹500 crore raised. Minor delays in capex funding for subsidiary Havix due to geopolitical issues are noted, with funds to be deployed by FY27. Unutilized amounts from other objectives were transferred to GCP.
Read the summary - Low impact
Senores Pharmaceuticals: Monitoring Agency Report for Q4FY26 Shows IPO Fund Utilization
Senores Pharmaceuticals submitted its Q4FY26 Monitoring Agency Report detailing IPO fund utilization. The ₹500 crore IPO proceeds show some implementation delays for specific projects, with revised completion timelines. Overall utilization is within the earmarked amount. Unutilized funds of ₹105.02 crore are primarily in fixed deposits.
Read the summary - High impact
Senores Pharma Q4 & FY26 Revenue Surges 66% to ₹190 Cr; PAT Jumps 104% to ₹37 Cr
Senores Pharmaceuticals reported Audited Consolidated Financial Results for Q4 & FY26 ended March 31, 2026. Q4 FY26 saw Total Income rise 66% to ₹190 Cr, EBITDA up 219% to ₹62 Cr, and PAT grow 104% to ₹37 Cr. FY26 Total Income increased 65% to ₹664 Cr, EBITDA rose 114% to ₹200 Cr, and PAT grew 108% to ₹122 Cr. The company also highlighted strategic acquisitions and joint ventures.
Read the summary - Medium impact
Senores Pharmaceuticals Board Approves FY26 Results, Appoints New Internal Auditor
Senores Pharmaceuticals reported its audited consolidated and standalone financial results for the quarter and fiscal year ended March 31, 2026. The Board also approved the appointment of Sharp & Tannan Associates as the new Internal Auditor for FY 2026-27. Mr. Vinay Kumar Mishra resigned as Company Secretary and Compliance Officer, effective June 10, 2026.
Read the summary - Medium impact
Senores Pharma Board Approves FY26 Audited Results; Company Secretary Resigns
Senores Pharmaceuticals' Board approved audited FY26 results with an unmodified auditor opinion. Mr. Vinay Kumar Mishra resigned as Company Secretary & Compliance Officer, effective June 10, 2026. Sharp & Tannan Associates appointed as Internal Auditor for FY27.
Read the summary - Low impact
Senores Pharmaceuticals Announces Q4FY26 Earnings Conference Call on May 14, 2026
Senores Pharmaceuticals will host its Q4FY26 earnings conference call on May 14, 2026, at 5:00 PM IST, post the release of financial results for the period ending March 31, 2026. Management will discuss results with analysts.
Read the summary - Low impact
Senores Pharma files annual disclosure on share encumbrance by promoters
Senores Pharmaceuticals Limited filed its annual disclosure on share encumbrance by promoters, including Mr. Swapnil Jatinbhai Shah. The filing, as per SEBI Takeover Regulations, covers encumbrances during the financial year ending March 31, 2026.
Read the summary - Low impact
Senores Pharma Files Reconciliation of Share Capital Audit Report for Q4FY26
Senores Pharmaceuticals submitted its Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026. All 4,60,53,588 shares are in dematerialized form. The company also noted the issuance of 11,70,000 warrants on March 28, 2026, and management changes effective March 17, 2026.
Read the summary - Low impact
Senores Pharma Receives SEBI Compliance Certificate for Dematerialization
Senores Pharmaceuticals Limited received a SEBI compliance certificate for the quarter ending March 31, 2026. This confirms processing of dematerialisation requests and cancellation of physical certificates, with depositories updated as registered owners within timelines.
Read the summary - High impact
Senores Pharma Forms US Joint Venture for Federal & Defense Sector Supplies
Senores Pharmaceuticals has formed a Joint Venture named Amerisyn, LLC with a strategic partner in the US. This JV aims to facilitate the supply of its products to the U.S. Federal Government, veterans affairs, and military supply contracts. The company expects this to be a significant driver of international business growth.
Read the summary - Medium impact
Senores Pharma forms US step-down subsidiary Amerisyn, LLC
Senores Pharmaceuticals' US subsidiary formed Amerisyn, LLC via a joint venture. SPI subscribed to 70% membership interest in Amerisyn, making it a step-down subsidiary. The agreement was dated April 2, 2026.
Read the summary - Medium impact
Senores Pharma Allots 11.7 Lakh Warrants Worth ₹95 Cr on Preferential Basis
Senores Pharmaceuticals approved the allotment of 11.7 lakh warrants convertible into equity shares. The total issue size is ₹95.004 Crore, with ₹23.751 Crore received upfront. The exercise price is ₹812 per warrant, and conversion is expected within 18 months.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio